Nicole Albright
Optometrist · Calumet City, ILNPI 1790949949
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Glaukos Corporation at 53.2% of the total. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $74.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$8K
- Bausch & Lomb Americas Inc.$742
- Alcon$714
- Mallinckrodt Hospital Products Inc.$527
- Coopervision Inc.$507
- AbbVie$468
- plus $4K from 21 others
What the payments were for
- Consulting fees$3,50024%
- Speaking & faculty fees$3,57525%
- Travel & lodging$4423%
- Food & beverage$6,49845%
- Entertainment$4223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 13 | $7,677 |
| Bausch & Lomb Americas Inc. | 24 | $742 |
| Alcon | 24 | $714 |
| Mallinckrodt Hospital Products Inc. | 11 | $527 |
| Coopervision Inc. | 6 | $507 |
| AbbVie(2 entities) | 14 | $468 |
| Optos, Inc. | 7 | $422 |
| Sun Pharmaceutical Industries Inc. | 7 | $412 |
| Amgen(2 entities) | 13 | $395 |
| Oyster Point Pharma, Inc. | 14 | $380 |
| Biotissue Holdings Inc. | 10 | $365 |
| Dompe US, Inc. | 6 | $350 |
| Harrow Eye, LLC | 6 | $338 |
| Kala Pharmaceuticals, Inc. | 7 | $243 |
| Tarsus Pharmaceuticals, Inc. | 6 | $200 |
| Aerie Pharmaceuticals, Inc. | 3 | $144 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Maculogix, Inc. | 3 | $115 |
| Novartis | 6 | $105 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $60 |
| Shire North American Group Inc | 3 | $45 |
| Astellas Pharma US Inc | 2 | $35 |
| AstraZeneca | 1 | $22 |
| Johnson & Johnson Vision Care, Inc. | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Tearlab Corp | 2 | $12 |
| LKC Technologies, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject W$1,050
- iStent Trabecular Micro-Bypass Stent System$500
- iStent inject Trabecular Micro-Bypass Stent System$500
- CEQUA$271
- PANORAMIC OPHTHALMOSCOPE$268
- OCT OPHTHALMOSCOPE$268
- ACTHAR$263
- Oxervate$250
- VEVYE$191
- MiSight Contact Lens$175
- NFC-700$134
- TEPEZZA$125
- INFUSE MULTIFOCAL$125
- Auvelity$125
- REVIVE$125
- TYRVAYA$123
- EYSUVIS$117
- Prokera$110
- AmnioGraft$110
- Rocklatan$107
How this compares
$14,437 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 97 | $122,526 |
| XiidraLifitegrast | 69 | $113,628 |
| LumiganBimatoprost | 66 | $34,532 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $23,380 |
| VyzultaLatanoprostene Bunod | 36 | $23,053 |
| Cyclosporine | 33 | $14,752 |
| TyrvayaVarenicline Tartrate | 16 | $8,824 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $6,428 |
| Latanoprost | 295 | $2,585 |
| Brimonidine Tartrate | 49 | $1,694 |
| Travoprost | 19 | $1,509 |
| Prednisolone Acetate | 56 | $1,243 |
| Azelastine Hcl | 20 | $485 |
| Ketorolac Tromethamine | 18 | $455 |
| Dorzolamide Hcl | 18 | $450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $468 | $163,486176 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $742 | $136,681105 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $144 | $23,38036 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $380 | $8,82416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.
Other optometrist in Calumet City
- Pamela LoweChicago$447K
- Jeffrey LewisChampaign$394K
- Adeyinka AdewaleGodfrey$391K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Steven EidenDeerfield$259K
- Peter KehoeGalesburg$167K
- Gulroop HansraDowners Grove$151K
- Treacy AdamoHinsdale$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.